CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) William Blair's 45th Annual Growth Stock Conference June 3, 2025 12:20 PM ET Company Participants Raju Prasad - Chief Financial Officer Conference Call Participants Sami Corwin - William Blair Sami Corwin Hi, everyone. We're going to get started.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies
CRSP enters into a strategic partnership with Sirius Therapeutics for developing novel siRNA Therapies.
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
Ever since scientists began mapping the human genome, gene editing has always been the end goal. The idea once seemed like something out of a science fiction novel, but it's here today and CRSPR Therapeutics AG NASDAQ: CRSP is leading the way.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 Monster Stocks to Hold for the Next 10 Years
The best investments are often stocks of companies offering goods and services that are perpetually in demand. Think entertainment, healthcare, or more recently, some consumer technologies.
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)
CRISPR Therapeutics' stock is down 20% since March, with ongoing high cash burn despite a robust $1.86 billion cash position. Casgevy's commercialization is slow, with over 65 treatment centers active but no recognized revenue yet, reflecting a complex administration process and gradual gene therapy adoption. Regulatory uncertainties under Dr. Vinay Prasad's FDA leadership could delay approvals, impacting CRISPR's gene and cell therapy timelines.
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks
CRSP reports wider-than-expected first-quarter loss. Revenues also miss estimates.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.43 per share a year ago.
CRISPR Therapeutics (CRSP) Short Sellers Have A Lot Riding on Earnings
Shares of CRISPR Therapeutics (NASDAQ:CRSP) can't seem to catch a break, now down close to 8% year to date and more than 80% from now-distant 2021 all-time highs.
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts
Gene therapy stocks like CRISPR Therapeutics and Intellia Therapeutics are facing significant volatility in 2025, influenced by market instability and regulatory uncertainties. CRSP is better positioned to navigate near-term challenges with a strong cash reserve and upcoming product launches, justifying an upgrade to 'Strong Buy.' NTLA, despite promising product candidates, faces higher risks and requires significant cost reductions to extend its cash runway, maintaining a "Buy" rating for high-risk investors.
